MktsMarkets

4D Molecular Therapeutics, Inc.
NASDAQ: FDMTKey statistics
FDMT News
Stories mentioning FDMT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 3,047 | 85,090 | 90.00 | 15.00 | 14.00 | 1.00 | 3.00 | 5.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | 76,667 | 70,375 | 61,275 | 59,471 | 53,635 | 56,118 | 51,135 | 42,461 |
| Operating Income (Loss) | (73,620) | 14,715 | (61,185) | (59,456) | (53,621) | (56,117) | (51,132) | (42,456) |
| Interest Income | 4,864 | 4,704 | 4,330 | 4,859 | 5,582 | 6,467 | 7,290 | 7,548 |
| Interest Expense | ||||||||
| Other Expense | (4.00) | (22.00) | (21.00) | (61.00) | 67.00 | (21.00) | (1.00) | (45.00) |
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (68,760) | 19,397 | (56,876) | (54,658) | (47,972) | (49,671) | (43,843) | (34,953) |
| Earnings Per Share (Basic) | (1.01) | 0.33 | (1.01) | (0.98) | (0.86) | (0.92) | (0.79) | (0.63) |
| Earnings Per Share (Diluted) | (1.01) | 0.33 | (1.01) | (0.98) | (0.86) | (0.92) | (0.79) | (0.63) |
| Weighted Average Shares Outstanding (Basic) | 68,065 | 57,930 | 56,126 | 55,927 | 55,744 | 53,944 | 55,554 | 55,283 |
| Weighted Average Shares Outstanding (Diluted) | 68,065 | 57,930 | 56,126 | 55,927 | 55,744 | 53,944 | 55,554 | 55,283 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About FDMT
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is a stock listed on the Nasdaq Stock Market under the ticker symbol FDMT. It last traded at $12.48 (Nov 9, 2026, 4:00 PM ET), up 1.9% on the day. That gives 4D Molecular Therapeutics a market capitalisation of $676.7M.
Over the past 52 weeks FDMT has traded between $6.96 and $16.93.
Revenue for the quarter ended Mar 31, 2026 was $3.0M; a net loss of $68.8M. Revenue was up 21664% from $14.0K in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $3.0M | -$68.8M | -2256.6% |
| Dec 31, 2025 | $85.1M | $19.4M | 22.8% |
| Sep 30, 2025 | $90.0K | -$56.9M | -63195.6% |
| Jun 30, 2025 | $15.0K | -$54.7M | -364386.7% |
From 4D Molecular Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…